registry-only
Products and companies known so far only from a trial registry entry, with little else published. 101 records carry it: 86 drugs, 15 companies.
Related tags
By kind
101 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Adavosertib Adavosertib is an oral serine/threonine kinase inhibitor from AstraZeneca, in registered phase 2 trials for triple-negative breast cancer. | Phase 2 | Triple-negative breast cancer | none | pipeline | |
Alisertib Alisertib is an oral serine/threonine kinase inhibitor from Puma Biotechnology, Inc., in registered phase 2 trials for small-cell lung cancer. | Phase 2 | Small-cell lung cancer | none | pipeline | |
AMO959 AMO959 AMO959 is a small-molecule inhibitor from Novartis Pharmaceuticals, in registered phase 2 trials for prostate cancer. | Phase 2 | Prostate cancer | none | pipeline | |
AMT-116 AMT-116 AMT-116 is an antibody-drug conjugate from Multitude Therapeutics Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer. | Phase 2 | Non-small-cell lung cancer, Small-cell lung cancer | none | pipeline | |
ARD103 ARD103 ARD103 is a car-t cell therapy from ARCE Therapeutics, Inc., in registered phase 2 trials for acute myeloid leukaemia, myelodysplastic syndromes / neoplasms. | Phase 2 | Acute myeloid leukaemia, Myelodysplastic syndromes / neoplasms | none | pipeline | |
AU-007 AU-007 AU-007 is a monoclonal antibody from Aulos Bioscience, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer. | Phase 2 | Metastatic cancer, Melanoma, Non-small-cell lung cancer | none | pipeline | |
AVZO-023 AVZO-023 AVZO-023 is a small-molecule inhibitor from Avenzo Therapeutics, Inc., in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
AZD0120 AZD0120 AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma. | Phase 3 | Multiple myeloma | none | pipeline | |
AZD8421 AZD8421 AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer. | Phase 2 | Ovarian cancer | none | pipeline | |
Balstilimab Balstilimab is a monoclonal antibody from Agenus Inc., in registered phase 2 trials for colorectal cancer. | Phase 2 | Colorectal cancer | none | pipeline | |
Befotertinib Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer. | Approved2023🇨🇳 | Non-small-cell lung cancer | none | pipeline | |
Beijing Gene Key Life Technology Beijing, China, CN Beijing Gene Key Life Technology is a Chinese developer in Beijing that sponsors 2 registered cancer trials of GKL-006. | none | none | china | ||
Beijing Konruns Pharmaceutical Beijing, China, CN Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1. | none | none | china | ||
Beijing Mabworks Biotech Beijing, China, CN Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303. | none | none | china | ||
Beijing Pearl Biotechnology Limited Liability Company Beijing, China, CN Beijing Pearl Biotechnology Limited Liability Company is a Chinese developer in Beijing that sponsors 3 registered cancer trials of PLB1001 and Temozolomide. | none | none | china | ||
Beijing Scitech-Mq Pharmaceuticals Beijing, China, CN Beijing Scitech-Mq Pharmaceuticals is a Chinese developer in Beijing that sponsors 3 registered cancer trials of ST-1898. | none | none | china | ||
Beijing Tide Pharmaceutical Beijing, China, CN Beijing Tide Pharmaceutical is a Chinese developer in Beijing that sponsors 2 registered cancer trials of TCC1727. | none | none | china | ||
Bexmarilimab Bexmarilimab is a monoclonal antibody from Faron Pharmaceuticals Ltd, in registered phase 2 trials for acute myeloid leukaemia, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, myelodysplastic syndromes / neoplasms. | Phase 2 | Acute myeloid leukaemia, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Myelodysplastic syndromes / neoplasms | none | pipeline | |
Binhui Biopharmaceutical Wuhan, China, CN Binhui Biopharmaceutical is a Chinese developer in Wuhan that sponsors 4 registered cancer trials of OH2 and HX008. | none | none | china | ||
Boserolimab Boserolimab is a monoclonal antibody from Merck Sharp & Dohme LLC, in registered phase 2 trials for non-small-cell lung cancer. | Phase 2 | Non-small-cell lung cancer | none | pipeline | |
Camonsertib Camonsertib is an oral serine/threonine kinase inhibitor from Hoffmann-La Roche, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Chengdu Zenitar Biomedical Technology Chengdu, China, CN Chengdu Zenitar Biomedical Technology is a Chinese developer in Chengdu that sponsors 6 registered cancer trials of Purinostat and Purinostat Mesylate. | none | none | china | ||
CT3001 CT3001 CT3001 is a small-molecule inhibitor from Crossignal Therapeutics, Inc., in registered phase 2 trials for colorectal cancer, pancreatic ductal adenocarcinoma. | Phase 2 | Colorectal cancer, Pancreatic ductal adenocarcinoma | none | pipeline | |
CYH33 CYH33 CYH33 is a small-molecule inhibitor from Haihe Biopharma Co., Ltd., in registered phase 2 trials for ovarian cancer. | Phase 2 | Ovarian cancer | none | pipeline | |
DOC1021 DOC1021 DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma. | Phase 2 | Glioma & glioblastoma, Melanoma | none | pipeline | |
DR-01 DR-01 DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas. | Phase 2 | Peripheral T-cell lymphomas | none | pipeline | |
EIK1005 EIK1005 EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer. | Phase 2 | Colorectal cancer, Endometrial cancer | none | pipeline | |
Emavusertib Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours. | Phase 2 | Chronic lymphocytic leukaemia, Brain and spinal cord tumours | none | pipeline | |
ENB003 ENB003 ENB003 is a small-molecule antagonist from ENB Therapeutics, Inc, in registered phase 2 trials for melanoma. | Phase 2 | Melanoma | none | pipeline | |
Evexomostat Evexomostat is a small-molecule inhibitor from SynDevRx, Inc., in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
EVM14 EVM14 EVM14 is a cancer vaccine from Everest Medicines (Beijing) Co., Ltd., in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Farletuzumab ecteribulin Farletuzumab ecteribulin is an antibody-drug conjugate from Eisai Inc., in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Feladilimab Feladilimab is a monoclonal antibody from GlaxoSmithKline, in registered phase 2 trials for multiple myeloma. | Phase 2 | Multiple myeloma | none | pipeline | |
Flonoltinib Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms. | Phase 2 | Myeloproliferative neoplasms | none | pipeline | |
Fluzoparib Fluzoparib is an oral parp inhibitor from Risen (Suzhou) Pharma Tech Co., Ltd., in registered phase 2 trials for metastatic cancer. | Approved2020🇨🇳 | Metastatic cancer | none | pipeline | |
Gecacitinib Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer. | Phase 2 | Cervical cancer | none | pipeline | |
Henan Genuine Biotech Henan, China, CN Henan Genuine Biotech is a Chinese developer in Henan that sponsors 2 registered cancer trials of GEN-725 and Dositinib. | none | none | china | ||
HST-1011 HST-1011 HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
ImmVira Pharma Shenzhen, China, CN ImmVira Pharma is a Chinese developer in Shenzhen that sponsors 3 registered cancer trials of Herpes Virus C5252 and T3011. | none | none | china | ||
IMP1734 IMP1734 IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Inlexisertib Inlexisertib is an oral serine/threonine kinase inhibitor from Deciphera Pharmaceuticals, LLC, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
IPG1094 IPG1094 IPG1094 is a small-molecule inhibitor from Nanjing Immunophage Biotech Co., Ltd, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Jacobio Pharmaceuticals Beijing, China, CN Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485. | none | none | china | ||
JBI-802 JBI-802 JBI-802 is a small-molecule inhibitor from Jubilant Therapeutics Inc., in registered phase 2 trials for myeloproliferative neoplasms, chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms. | Phase 2 | Myeloproliferative neoplasms, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms | none | pipeline | |
JMT203 JMT203 JMT203 is a monoclonal antibody from Shanghai JMT-Bio Inc., in registered phase 2 trials for non-small-cell lung cancer, pancreatic ductal adenocarcinoma, colorectal cancer. | Phase 2 | Non-small-cell lung cancer, Pancreatic ductal adenocarcinoma, Colorectal cancer | none | pipeline | |
LP-184 LP-184 LP-184 is a small-molecule inhibitor from Lantern Pharma Inc., in registered phase 2 trials for triple-negative breast cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma. | Phase 2 | Triple-negative breast cancer, Non-small-cell lung cancer, Pancreatic ductal adenocarcinoma | none | pipeline | |
LVGN6051 LVGN6051 LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma. | Phase 2 | Head and neck squamous cell carcinoma | none | pipeline | |
Merestinib Merestinib is an oral kinase inhibitor from Eli Lilly and Company, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
MHB036C MHB036C MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
MHB039A MHB039A MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Mitazalimab Mitazalimab is an antibody-drug conjugate from Alligator Bioscience AB, in registered phase 2 trials for pancreatic ductal adenocarcinoma. | Phase 2 | Pancreatic ductal adenocarcinoma | none | pipeline | |
Nanjing Immunophage Biotech Nanjing, China, CN Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236. | none | none | china | ||
NP137 NP137 NP137 is a monoclonal antibody from NETRIS Pharma, in registered phase 2 trials for endometrial cancer, cervical cancer. | Phase 2 | Endometrial cancer, Cervical cancer | none | pipeline | |
NUV-1511 NUV-1511 NUV-1511 is a small-molecule inhibitor from Nuvation Bio Inc., in registered phase 2 trials for prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer. | Phase 2 | Prostate cancer, Pancreatic ductal adenocarcinoma, Ovarian cancer | none | pipeline | |
OBI-902 OBI-902 OBI-902 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
OBI-992 OBI-992 OBI-992 is an antibody-drug conjugate from OBI Pharma, Inc, in registered phase 2 trials for metastatic cancer. | Phase 2 | Metastatic cancer | none | pipeline | |
Onvansertib Onvansertib is an oral serine/threonine kinase inhibitor from Cardiff Oncology, in registered phase 2 trials for colorectal cancer. | Phase 2 | Colorectal cancer | none | pipeline | |
OR502 OR502 OR502 is a monoclonal antibody from OncoResponse, Inc., in registered phase 2 trials for metastatic cancer, melanoma, non-small-cell lung cancer. | Phase 2 | Metastatic cancer, Melanoma, Non-small-cell lung cancer | none | pipeline | |
Pamiparib Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer. | Approved2021🇨🇳 | Ovarian cancer | none | pipeline | |
Parsaclisib Parsaclisib is an oral pi3k inhibitor from Incyte Corporation, in registered phase 2 trials for diffuse large B-cell lymphoma. | Phase 2 | Diffuse large B-cell lymphoma | none | pipeline |
(showing the first 60)
The table above loads 60 of 101 records first and fetches the rest as you scroll, search or filter. This tag as JSON · table rows · API